Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.
Thomas Catinazzo, the Chief Financial Officer of Relay Therapeutics, sold 17,717 shares of the company's common stock on August 14, 2026, according to a filing with the Securities and Exchange Commission. The transaction took place at an average price of $19.74 per share, with a post-transaction value of $19.86 per share based on the market close on that day.
Relay Therapeutics is a clinical-stage precision medicine company headquartered in Cambridge, Massachusetts, and employs over 200 people. The company is currently valued at $4 billion. In the past year, Relay Therapeutics' shares have surged by 485%, which has boosted investor confidence in the company's drug development pipeline.
As a pre-revenue biotechnology enterprise, Relay Therapeutics' success is contingent on the clinical efficacy and regulatory approval of its small molecule candidates, particularly RLY-4008, which targets unmet medical needs in oncology with unique mechanisms of action.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
